Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients.
Burrows
L
L
Mount Sinai Medical Center, New York, New York 10029, USA.
Knight
R
R
Genyk
Y
Y
Schwartz
B
B
Moran
V
V
Anand
R
R
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D016572:Cyclosporine / Q000009:adverse effects*; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use; D005260:Female; D000077340:Fluvastatin; D005885:Gingival Hyperplasia / Q000139:chemically induced; D006628:Hirsutism / Q000139:chemically induced; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008148:Lovastatin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D005229:Fatty Acids, Monounsaturated; D007166:Immunosuppressive Agents; D007211:Indoles; D000077340:Fluvastatin; D016572:Cyclosporine; D008148:Lovastatin; D017035:Pravastatin; D016559:Tacrolimus